CRSP:NASDAQ
Crispr Therapeutics AG
$52.08
arrow_upward
+0.12%(+0.060) 1D
$52.06
arrow_downward
-0.04% (-0.020)bedtimeAfter hours
Closed: Jun 3, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CRSP...
Open
$51.46
High
$52.28
Low
$50.52
Mkt. cap
5.02B
Avg. vol.
1.79M
Volume
1.27M
52-wk high
$78.48
52-wk low
$37.02
EPS
-$6.21
Beta
1.31
Shares outstanding
96.45M
No. of employees
393
Open
$51.46
High
$52.28
Low
$50.52
Mkt. cap
5.02B
Avg. vol.
1.79M
Volume
1.27M
52-wk high
$78.48
52-wk low
$37.02
EPS
-$6.21
Beta
1.31
Shares outstanding
96.45M
No. of employees
393
News stories
From sources across the web
Yahoo Finance
·
11 hours ago
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential
TradingView
·
11 hours ago
CRSP: Multiple late-stage assets and data readouts position the pipeline for major milestones in 2024
Yahoo Finance
·
12 hours ago
Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?
Profile
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
About Crispr Therapeutics AG
CEOSamarth Kulkarni
Employees393
Founded2013
HeadquartersZug, Zug, Switzerland
SectorBiotechnology
Websitecrisprtx.com
AI content may include mistakes. Learn more